Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.

Medical sciences (Basel, Switzerland) - 18 Sept 2025

Shalata Walid, Naamneh Rashad, Najjar Wenad, Abu Amna Mahmoud, Asla Mohnnad, Agbarya Abed, Brenner Ronen, Abu Jama Ashraf, Abu Yasin Nashat, Abu Juda Mhammad, Abu Zeid Ez El Din, Rouvinov Keren, Yakobson Alexander

Abstract excerpt

BACKGROUND: Brain metastases (BMs) are a common and challenging complication of non-small cell lung cancer (NSCLC), historically associated with a poor prognosis. The development of targeted therapies, specifically tyrosine kinase inhibitors (TKIs) for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene alterations, has significantly improved treatment outcomes. METHODS: This article...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Share to Tyrosine Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40981198
DOI: 10.3390/medsci13030200
PMCID: PMC12452606

Genes

ALK
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.PMID 40981198Read ↗

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.Semantic proximity Read ↗

Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.Semantic proximity Read ↗

Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?Semantic proximity Read ↗

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?Semantic proximity Read ↗

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.Semantic proximity Read ↗

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies.Semantic proximity Read ↗

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Semantic proximity Read ↗

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSemantic proximity Read ↗

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.